This invention is related to novel cyclopentyl derivatives of the following general Formula (I), wherein X is methylene, oxygen, sulphur or a NR.sup.7 group; R.sup.1 is a straight or branched C.sub.1-C.sub.8 alkyl or C.sub.3-C.sub.8 alkenylene or C.sub.3-C.sub.8 alkynylene chain, optionally substituted with CF.sub.3, phenyl, phenoxy or naphthyl, the aromatic rings optionally substituted by one or more C.sub.1-C.sub.4 alkyl, halogens, trifluoromethyl, hydroxy or C.sub.1-.sub.C4 alkoxy groups; R.sup.2, R.sup.3 are independently hydrogen, a C.sub.1-C.sub.3 alkyl chain, halogen, trifluoromethyl, hydroxy or C.sub.1-C.sub.4 alkoxy groups; R.sup.4, R.sup.5, R.sup.6, R.sup.7 are independently hydrogen or C.sub.1-C.sub.6 alkyl; and the pharmaceutically acceptable salts thereof that are active as sodium and/or calcium channel modulators and therefor useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.